Early identification of neoadjuvant therapy non-response via multimodal immune-imaging biomarkers in breast cancer - Scorecard - MDSpire

Early identification of neoadjuvant therapy non-response via multimodal immune-imaging biomarkers in breast cancer

  • By

  • Xiangyuan Zhou

  • Xianming Huang

  • Lan Liu

  • Xiaoqin Cai

  • Han Li

  • Zhikang Sun

  • Zongqing Qiu

  • Jinxiu Zhong

  • Tenghua Yu

  • Qiao Zeng

  • June 10, 2026

  • 0 min

Share

Clinical Scorecard: Timely Detection of Non-Response to Neoadjuvant Therapy Using Multimodal Immune-Imaging Biomarkers in Breast Cancer

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationPatients with locally advanced or high-risk early-stage breast cancer undergoing neoadjuvant therapy (n=112).
Care Setting

Key Highlights

  • additional_info

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Incorporate longitudinal MRI and inflammatory biomarker assessments, including NLR, MLR, and PLR.

      Risks

        Patient & Prescribing Data

        Include specific treatment regimens used in the study.

        Clinical Best Practices

        • recommendation

        Related Resources & Content

          Original Source(s)

          Early identification of neoadjuvant therapy non-response via multimodal immune-imaging biomarkers in breast cancer

          • by Xiangyuan Zhou, Xianming Huang, Lan Liu, Xiaoqin Cai, Han Li, Zhikang Sun, Zongqing Qiu, Jinxiu Zhong, Tenghua Yu, Qiao Zeng

          • June 10, 2026

          Related Content

          The efficacy of angiogenesis inhibitors combined with chemotherapy in advanced breast cancer: a systematic review and meta-analysis

          POC1A promotes malignant phenotypes in non-triple-negative breast cancer cell models with EMT- and Wnt/β-catenin-related alterations

          Development and internal validation of a risk prediction model for ipsilateral upper-limb lymphedema following breast cancer surgery